Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    1(33%)

    Phase Distribution

    Phase 1/2
    1
    33%
    Phase 2
    2
    67%

    Phase Distribution

    0

    Early Stage

    3

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1/2Combined phases
    1(33.3%)
    Phase 2Efficacy & side effects
    2(66.7%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(3)

    Detailed Status

    Not yet recruiting2
    Recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    N/A
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 1/21 (33.3%)
    Phase 22 (66.7%)

    Trials by Status

    not_yet_recruiting267%
    recruiting133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    recruitingphase_1_2

    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

    NCT06679036
    not_yet_recruitingphase_2

    An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

    NCT07061210
    not_yet_recruitingphase_2

    Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

    NCT06738745

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT06679036Phase 1/2

    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

    Recruiting
    NCT07061210Phase 2

    An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

    Not Yet Recruiting
    NCT06738745Phase 2

    Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

    Not Yet Recruiting

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3